Top news of the week: 10.03.2020.
#vaccine #coronavirus #biotechnology #Antibiotics #biospace #lifesciences #pharma #pharmaceuticals #Bankruptcy #COVID
Companies And Industries
RT @BiIndia: .@kiranshaw wanted to be a brewmaster before building the largest biotech company in India - by @pabsgill
https://t.co/0OLRwwSh4m https://t.co/GW7M5LVceV
OpenKiran Mazumdar Shaw wanted to be a brewmaster before building the largest biotech company in India
Biocon founder Kiran Mazumdar Shaw wanted to be a brewmaster before entering pharmaceuticals. In an interview with Twitter India, Shaw said the idea for Biocon
'Crazy hours, short nights': The inside story of how a buzzy biotech upstart developed a potential #coronavirus #vaccine in record time @moderna_tx via @dnabarcode https://t.co/gE7L6ou79V?
Open'Crazy hours, short nights': The inside story of how a buzzy biotech upstart developed a potential coronavirus vaccine in record time
The vaccine still needs at least 12 to 18 months of testing in people to determine if it's safe and works to prevent the coronavirus.
Biopharma equities caught in vortex of oil crash and coronavirus fears
The financial markets were delivered a one-two punch March 9 – a plunge in oil prices along with fears that the coronavirus is continuing to spread unabated. As a result, the Dow Jones ...
Pfizer mulling over COVID-19 R&D pact with BioNTech: report https://t.co/6CwevVWhgi https://t.co/sTzLb6PGx5
OpenPfizer mulling over COVID-19 R&D pact with BioNTech: report
Big Pharma Pfizer is already at work on antivirals aimed at dampening down COVID-19 in the already infected, but it's now mulling over a pact with partner BioNTech to develop a vaccine.
Biogen's early R&D chief Ghosh leaves to take Unity CEO post https://t.co/Rj6zlPtJJM https://t.co/NolY9V9Mf2
OpenBiogen's early R&D chief Ghosh leaves to take Unity CEO post
Biogen’s head of early R&D Anirvan Ghosh has left the company to take up the CEO position at Unity Biotechnology. The neuroscientist joins the longevity biotech after three years leading a ...
Melinta's #Bankruptcy Underlines Problems with the #Antibiotics Market
It's not the science. The science is there. It’s the market.
#biospace #lifesciences #biotechnology #pharma #pharmaceuticals
https://t.co/uQPnynBRjU
OpenMelinta's Bankruptcy Underlines Problems with the Antibiotics Market
Deerfield Management placed Melinta’s assets up for auction, but no other companies made competing bids, leaving Deerfield in control of the company’s assets.
Industry, academia pivot: Pipeline of #COVID-19 vaccine and therapeutic candidates doubles https://t.co/GMGC6DF4NB
OpenIndustry, academia pivot: Pipeline of COVID-19 vaccine and therapeutic candidates doubles
A list of biopharma companies and nonprofit entities, including academia, working feverishly to find a vaccine or antiviral treatment to address the rapidly spreading coronavirus, now known ...
Global spread of coronavirus puts financial markets into a tailspin
Concerns about the escalating global spread of COVID-19 panicked the markets big time at the close of the month. With investors rushing to the sidelines, it only took five days for the Dow ...